Opportunity to accelerate your company with Takeda Canada through dedicated funding for a proof-of-concept project. The Takeda Canada Innovation Challenge opens on January 10, 2022 and will accept applications until February 6, 2022…. Read More
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10… Read More
ZURICH, CH – Novartis (NOVN.S)said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting… Read More
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant. The data confirmed… Read More
Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted… Read More
